Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 2/20 | 0.67 |
| ▸ | GRPR | P30550 | 2/20 | 0.67 |
| ▸ | CALCR | P30988 | 4/20 | 0.66 |
| ▸ | GLP1R | P43220 | 10/20 | 0.65 |
| ▸ | GCGR | P47871 | 7/20 | 0.65 |
| ▸ | CCKBR | P32239 | 2/20 | 0.64 |
| ▸ | GIPR | P48546 | 4/20 | 0.61 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.61 |
| ▸ | NPY1R | P25929 | 1/20 | 0.61 |
| ▸ | NPY2R | P49146 | 1/20 | 0.61 |
| ▸ | NPY4R | P50391 | 1/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.61 |
| ▸ | CALCA | P06881 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29020839 | 1.00 | NMBR (0.67) | NMBRGRPRCALCRGLP1RGCGR | |
| Acetic Acid SCHEMBL29378226 | 0.99 | NMBR (0.66) | NMBRGRPRCALCRGLP1RGCGR | |
| SCHEMBL25311922 | 0.99 | NMBR (0.65) | NMBRGRPRCALCRGLP1RGCGR | |
| SCHEMBL31359434 | 0.96 | CALCR (0.71) | NMBRGRPRCALCRGLP1RGCGR | |
| SCHEMBL29588042 | 0.94 | CALCR (0.65) | NMBRGRPRCALCRGLP1RGCGR | |
| SCHEMBL29588160 | 0.94 | CALCR (0.66) | NMBRGRPRCALCRGLP1RGCGR | |
| SCHEMBL20534064 | 0.94 | CXCR4 (0.69) | GLP1RGCGRGIPRCXCR4NPY1R | |
| SCHEMBL29020816 | 0.94 | CXCR4 (0.69) | GLP1RGCGRGIPRCXCR4NPY1R | |
| SCHEMBL29587876 | 0.94 | CALCR (0.65) | NMBRGRPRCALCRGLP1RGCGR | |
| SCHEMBL29588702 | 0.93 | CALCR (0.64) | NMBRGRPRCALCRGLP1RGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4098273-A1 | COMBINATION THERAPY OF HBV AND HDV INFECTION | Myr GmbH (DE) | 2022-12-07 | — | — | EP | claimed |
| EP-3204030-B1 | COMBINATION THERAPY OF HBV AND HDV INFECTION | MYR GMBH (DE) | 2022-04-27 | — | — | EP | claimed |
| US-20220040178-A1 | COMBINATION THERAPY OF HBV AND HDV INFECTION | MYR GMBH (DE) | 2022-02-10 | — | — | US | claimed |
| US-20250345389-A1 | COMBINATION THERAPIES | GILEAD SCIENCES INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4098273-A1 | COMBINATION THERAPY OF HBV AND HDV INFECTION | Myr GmbH (DE) | 2022-12-07 | — | — | EP | disclosed |
| EP-3204030-B1 | COMBINATION THERAPY OF HBV AND HDV INFECTION | MYR GMBH (DE) | 2022-04-27 | — | — | EP | disclosed |
| US-20220040178-A1 | COMBINATION THERAPY OF HBV AND HDV INFECTION | MYR GMBH (DE) | 2022-02-10 | — | — | US | disclosed |
| US-20210196786-A1 | THERAPY OF ATHEROSCLEROSIS, PRIMARY BILIARY CIRRHOSIS AND NRLP3 INFLAMMASOME-ASSOCIATED DISEASE BY HTCP INHIBITORS | MYR GMBH (DE) | 2021-07-01 | — | — | US | disclosed |
| US-10925925-B2 | Therapy of atherosclerosis, primary biliary cirrhosis and NRLP3 inflammasome-associated disease by HTCP inhibitors | MYR GMBH (DE) | 2021-02-23 | — | — | US | disclosed |
| EP-3392267-A1 | THERAPY OF ATHEROSCLEROSIS, PRIMARY BILIARY CIRRHOSIS AND NRLP3 INFLAMMASOME-ASSOCIATED DISEASE BY HTCP INHIBITORS | Myr GmbH (DE) | 2018-10-24 | — | — | EP | disclosed |
| US-20180296634-A1 | THERAPY OF ATHEROSCLEROSIS, PRIMARY BILIARY CIRRHOSIS AND NRLP3 INFLAMMASOME-ASSOCIATED DISEASE BY HTCP INHIBITORS | MYR GMBH (DE) | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296634-A1 | THERAPY OF ATHEROSCLEROSIS, PRIMARY BILIARY CIRRHOSIS AND NRLP3 INFLAMMASOME-ASSOCIATED DISEASE BY HTCP INHIBITORS | SLC10A1, NR1H4, SLC10A2 | NMBR 275/4885GRPR 520/4885CALCR 326/4885 |
| US-20210196786-A1 | THERAPY OF ATHEROSCLEROSIS, PRIMARY BILIARY CIRRHOSIS AND NRLP3 INFLAMMASOME-ASSOCIATED DISEASE BY HTCP INHIBITORS | SLC10A1, NR1H4, SLC10A2 | NMBR 275/4885GRPR 520/4885CALCR 326/4885 |
| US-10925925-B2 | Therapy of atherosclerosis, primary biliary cirrhosis and NRLP3 inflammasome-associated disease by HTCP inhibitors | SLC10A1, NR1H4, SLC10A2 | NMBR 275/4885GRPR 520/4885CALCR 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.